Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Unusually active option classes on open August 4th » 09:40
08/04/20
08/04
09:40
08/04/20
09:40
PSTG

Pure Storage

$18.11 /

+ (+0.00%)

, ARCC

Ares Capital

$14.44 /

+ (+0.00%)

, ADT

ADT Inc.

$13.42 /

+ (+0.00%)

, BP

BP

$22.09 /

+ (+0.00%)

, VALE

Vale

$11.43 /

+ (+0.00%)

, AZN

AstraZeneca

$56.80 /

+ (+0.00%)

, INTC

Intel

$48.29 /

+ (+0.00%)

, PINS

Pinterest

$36.07 /

+ (+0.00%)

, MO

Altria Group

$41.00 /

+ (+0.00%)

Unusual total active…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PSTG Pure Storage
$18.11 /

+ (+0.00%)

ARCC Ares Capital
$14.44 /

+ (+0.00%)

ADT ADT Inc.
$13.42 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

VALE Vale
$11.43 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

06/18/20 Deutsche Bank
Pure Storage initiated with a Hold at Deutsche Bank
06/17/20 Deutsche Bank
Pure Storage initiated with a Hold at Deutsche Bank
05/29/20 Lake Street
Pure Storage a share gainer with 'robust' subscription growth, says Lake Street
05/29/20 Northland
Pure Storage price target raised to $23 from $21 at Northland
ARCC Ares Capital
$14.44 /

+ (+0.00%)

05/07/20 Citi
Ares Capital price target raised to $15 from $13 at Citi
04/16/20 Raymond James
Ares Capital upgraded to Outperform at Raymond James on valuation
04/16/20 Raymond James
Ares Capital upgraded to Outperform from Market Perform at Raymond James
04/13/20 BofA
Ares Capital upgraded to Buy from Neutral at BofA
ADT ADT Inc.
$13.42 /

+ (+0.00%)

08/03/20 Goldman Sachs
ADT Inc. price target raised to $17 from $9 at Goldman Sachs
08/03/20 William Blair
Alarm.com downgraded at William Blair on ADT/Google overhang
08/03/20 William Blair
Alarm.com downgraded to Market Perform from Outperform at William Blair
08/03/20 Morgan Stanley
ADT Inc. price target raised to $17 from $7 at Morgan Stanley
BP BP
$22.09 /

+ (+0.00%)

07/16/20 Jefferies
BP upgraded to Buy from Hold at Jefferies
07/15/20 JPMorgan
BP price target raised to 425 GBp from 400 GBp at JPMorgan
07/14/20 Credit Suisse
BP price target lowered to 350 GBp from 360 GBp at Credit Suisse
07/01/20 Barclays
BP price target raised to 400 GBp from 380 GBp at Barclays
VALE Vale
$11.43 /

+ (+0.00%)

06/11/20 Deutsche Bank
Vale price target raised to $13 from $11 at Deutsche Bank
06/09/20 GLJ Research
Fortescue Metals upgraded to Hold from Sell at GLJ Research
06/05/20 Exane BNP Paribas
Vale upgraded to Outperform from Neutral at Exane BNP Paribas
06/03/20 UBS
Vale upgraded to Buy from Neutral at UBS
AZN AstraZeneca
$56.80 /

+ (+0.00%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
INTC Intel
$48.29 /

+ (+0.00%)

07:28 Today Jefferies
AMD price target raised to $95 from $86 at Jefferies
08/03/20 Roth Capital
MaxLinear price target raised to $35 from $30 at Roth Capital
08/03/20 Stifel
Stifel rises MaxLinear price target to $35 after completion of Home Gateway deal
07/31/20 Erste
Intel downgraded to Hold from Buy at Erste
PINS Pinterest
$36.07 /

+ (+0.00%)

08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Wedbush
Pinterest price target raised to $39 from $31 at Wedbush
08/03/20 DA Davidson
Pinterest price target raised to $28 from $19 at DA Davidson
08/03/20 JPMorgan
Pinterest price target raised to $37 from $26 at JPMorgan
MO Altria Group
$41.00 /

+ (+0.00%)

07/08/20
Fly Intel: Top five analyst downgrades
07/08/20 Barclays
Altria downgraded to Equal Weight on share losses at Barclays
07/08/20 Barclays
Altria Group downgraded to Equal Weight from Overweight at Barclays
07/07/20 Stifel
IQOS reduced exposure claim a 'win' for Philip Morris, Altria, says Stifel
PSTG Pure Storage
$18.11 /

+ (+0.00%)

ARCC Ares Capital
$14.44 /

+ (+0.00%)

ADT ADT Inc.
$13.42 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

VALE Vale
$11.43 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

  • 16
    Oct
PSTG Pure Storage
$18.11 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

VALE Vale
$11.43 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

ADT ADT Inc.
$13.42 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

VALE Vale
$11.43 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

PSTG Pure Storage
$18.11 /

+ (+0.00%)

ARCC Ares Capital
$14.44 /

+ (+0.00%)

ADT ADT Inc.
$13.42 /

+ (+0.00%)

BP BP
$22.09 /

+ (+0.00%)

VALE Vale
$11.43 /

+ (+0.00%)

AZN AstraZeneca
$56.80 /

+ (+0.00%)

INTC Intel
$48.29 /

+ (+0.00%)

PINS Pinterest
$36.07 /

+ (+0.00%)

MO Altria Group
$41.00 /

+ (+0.00%)

Earnings
Bayer sees FY20 core EPS EUR6.70-EUR6.90 vs. prior EUR7.00-EUR7.20 view » 06:33
08/04/20
08/04
06:33
08/04/20
06:33
BAYRY

Bayer

$0.00 /

+ (+0.00%)

The company is now…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

Earnings
Bayer reports Q2 core EPS up 5.3% to EUR1.59 » 06:32
08/04/20
08/04
06:32
08/04/20
06:32
BAYRY

Bayer

$0.00 /

+ (+0.00%)

Group sales in the second…

Group sales in the second quarter of 2020 declined by 2.5 percent on a currency- and portfolio-adjusted basis to 10.054 billion euros. Group EBITDA before special items rose by 5.6 percent to 2.883 billion euros, net of 12 million euros in negative currency effects. EBIT of the Bayer Group was minus 10.784 billion euros after net special charges of 12.511 billion euros. The special charges mainly comprised provisions for the agreements reached with regard to glyphosate, dicamba and PCBs. "Thanks to the growth in our agricultural business, we raised EBITDA before special items - and we did so in a challenging environment," said Werner Baumann, Chairman of the Board. "Our primary aim during the coronavirus pandemic remains the safety and wellbeing of our employees and the society in which we live and work."

ShowHide Related Items >><<
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

Periodicals
COVID-19 vaccine candidates impress, but investors wary, WSJ reports » 06:07
08/04/20
08/04
06:07
08/04/20
06:07
MRNA

Moderna

$77.98 /

+3.88 (+5.24%)

, PFE

Pfizer

$38.36 /

-0.125 (-0.32%)

Potential COVID-19…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$38.36 /

-0.125 (-0.32%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
PFE Pfizer
$38.36 /

-0.125 (-0.32%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
PFE Pfizer
$38.36 /

-0.125 (-0.32%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

  • 19
    May
  • 12
    Feb
PFE Pfizer
$38.36 /

-0.125 (-0.32%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

PFE Pfizer
$38.36 /

-0.125 (-0.32%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

PFE Pfizer
$38.36 /

-0.125 (-0.32%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

Yesterday
Hot Stocks
PPD, Inc. signs new service agreement with Pfizer » 09:07
08/03/20
08/03
09:07
08/03/20
09:07
PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, PPD

PPD, Inc.

$29.43 /

+0.19 (+0.65%)

PPD, Inc. (PPD) announced…

PPD, Inc. (PPD) announced it has signed a new three-year agreement with Pfizer (PFE) to provide drug development services to advance Pfizer's portfolio. PPD said in a release, "Under the terms of the agreement, Pfizer has the right to extend the term for additional two-year periods. Financial details of the agreement were not disclosed. The agreement builds on the companies' existing relationship, in which PPD provides wide-ranging expertise in global clinical development and laboratory services to support Pfizer's drug development initiatives across multiple therapeutic areas."

ShowHide Related Items >><<
PPD PPD, Inc.
$29.43 /

+0.19 (+0.65%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
PPD PPD, Inc.
$29.43 /

+0.19 (+0.65%)

06/04/20
Fly Intel: Top five analyst initiations
06/04/20 KeyBanc
PPD, Inc. initiated with an Overweight, $35 target at KeyBanc
06/03/20 KeyBanc
PPD, Inc. initiated with an Overweight at KeyBanc
05/08/20 Mizuho
PPD, Inc. price target raised to $29 from $22 at Mizuho
PPD PPD, Inc.
$29.43 /

+0.19 (+0.65%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

  • 06
    Feb
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

PPD PPD, Inc.
$29.43 /

+0.19 (+0.65%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

PPD PPD, Inc.
$29.43 /

+0.19 (+0.65%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

Recommendations
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies » 06:55
08/03/20
08/03
06:55
08/03/20
06:55
MRNA

Moderna

$74.10 /

-3.5 (-4.51%)

, PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, BNTX

BioNTech

$82.12 /

-1.895 (-2.26%)

, AZN

AstraZeneca

$55.77 /

-2.13 (-3.68%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee said he sees fast enrollment in the Phase 3 study of Moderna's (MRNA) COVID-19 vaccine, along with above-average infection rates in U.S. hot spots, leaving 70% odds that the trial could meet its primary endpoint before the end of October to early November based on the first or second interim. Yee believes Moderna's Phase 3 trial has a 65% chance of working and with data coming potentially as soon as October he thinks emergency use authorization approval is potentially possible by the end of 2020. He sees similar, if not earlier into September, timing for the vaccine candidate being studied by Pfizer (PFE) and BioNTech (BNTX), due to global enrollment and other minor details, Yee added. He also estimates Oxford and AstraZeneca's (AZN) data may read out by Fall given more EU based enrollment and infection rate sensitivities, the analyst noted.

ShowHide Related Items >><<
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

BNTX BioNTech
$82.12 /

-1.895 (-2.26%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

Hot Stocks
Elanco closes acquisition of Bayer Animal Health » 06:07
08/03/20
08/03
06:07
08/03/20
06:07
ELAN

Elanco

$23.62 /

+1.18 (+5.26%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Elanco Animal Health…

Elanco Animal Health (ELAN) announced it has closed the acquisition of Bayer Animal Health (BAYRY). The transaction, valued at $6.89B, expands Elanco's scale and capabilities, positioning the company for the long term as a leader in the attractive, durable animal health industry. Upon close, Bayer AG received $5.17B in cash, comprised of proceeds from the company's equity and tangible equity unit issuances in the first quarter of 2020 and debt financing from the Term Loan B priced in the first quarter of 2020 that closed with the transaction closing. Additionally, approximately 72.9M shares of Elanco Animal Health common stock were issued to Bayer AG. These shares will be subject to a lock up, where Bayer cannot sell any shares for the first 90 days. In the second 90 days, 50% of shares are eligible for sale and the remainder may be sold after 180 days. Moreover, Elanco has completed the required anti-trust divestures that had been previously announced. The divested products had 2019 revenue in the range of $120M-$140M.

ShowHide Related Items >><<
ELAN Elanco
$23.62 /

+1.18 (+5.26%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

ELAN Elanco
$23.62 /

+1.18 (+5.26%)

07/27/20 Evercore ISI
Evercore worried after deep dive into Elanco channel inventories
07/27/20 Cleveland Research
Elanco downgraded to Underperform from Neutral at Cleveland Research
06/05/20 Citi
Citi opens 'positive catalyst watch' on Elanco Animal Health
05/15/20 Citi
Elanco price target lowered to $27 from $35 at Citi
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
ELAN Elanco
$23.62 /

+1.18 (+5.26%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

  • 23
    Jan
BAYRY Bayer
$0.00 /

+ (+0.00%)

ELAN Elanco
$23.62 /

+1.18 (+5.26%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

ELAN Elanco
$23.62 /

+1.18 (+5.26%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 09:06
08/01/20
08/01
09:06
08/01/20
09:06
MSFT

Microsoft

$205.00 /

+1.135 (+0.56%)

, PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, AZN

AstraZeneca

$55.77 /

-2.13 (-3.68%)

, BMY

Bristol-Myers

$58.66 /

-0.22 (-0.37%)

, LLY

Eli Lilly

$150.24 /

-2.71 (-1.77%)

, GSK

GlaxoSmithKline

$40.31 /

+0.045 (+0.11%)

, JNJ

Johnson & Johnson

$145.78 /

-1.09 (-0.74%)

, MRK

Merck

$80.26 /

+1.21 (+1.53%)

, NVS

Novartis

$82.09 /

-2.115 (-2.51%)

, SNY

Sanofi

$52.43 /

-0.1 (-0.19%)

, MRNA

Moderna

$74.10 /

-3.5 (-4.51%)

, SNAP

Snap

$22.41 /

+ (+0.00%)

, TWTR

Twitter

$36.39 /

-0.34 (-0.93%)

, FB

Facebook

$253.82 /

+19.19 (+8.18%)

, GOOG

Alphabet

$1,482.46 /

-52.125 (-3.40%)

, GOOGL

Alphabet Class A

$1,487.69 /

-48.81 (-3.18%)

, AMZN

Amazon.com

$3,165.00 /

+114.03 (+3.74%)

, AAPL

Apple

$425.02 /

+39.88 (+10.35%)

, KODK

Eastman Kodak

$22.30 /

-7.53 (-25.24%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
MRK Merck
$80.26 /

+1.21 (+1.53%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
NVS Novartis
$82.09 /

-2.115 (-2.51%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
SNY Sanofi
$52.43 /

-0.1 (-0.19%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
MRNA Moderna
$74.10 /

-3.5 (-4.51%)

07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
SNAP Snap
$22.41 /

+ (+0.00%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/22/20
Fly Intel: Top five analyst downgrades
07/22/20 Oppenheimer
Snap price target raised to $28 from $18 at Oppenheimer
07/22/20 JPMorgan
Snap should be bought on any meaningful pullback, says JPMorgan
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
FB Facebook
$253.82 /

+19.19 (+8.18%)

07/31/20
Facebook price target raised to $300 from $290 at JPMorgan
07/31/20 Wedbush
Facebook price target raised to $300 from $250 at Wedbush
07/31/20 RBC Capital
Facebook price target raised to $320 from $271 at RBC Capital
07/31/20 Raymond James
Facebook price target raised to $280 from $240 at Raymond James
GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 Guggenheim
Alphabet price target raised to $1,725 from $1,580 at Guggenheim
07/31/20 Raymond James
Alphabet price target raised to $1,700 from $1,425 at Raymond James
07/31/20 Oppenheimer
Alphabet price target raised to $1,685 from $1,445 at Oppenheimer
GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

07/31/20 RBC Capital
Alphabet price target raised to $1,700 from $1,500 at RBC Capital
07/31/20 Morgan Stanley
Alphabet price target raised to $1,760 from $1,700 at Morgan Stanley
07/31/20 Barclays
Alphabet price target raised to $1,800 from $1,600 at Barclays
AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

07/31/20 BMO Capital
Amazon.com price target raised to $3,700 from $3,500 at BMO Capital
07/31/20 RBC Capital
Amazon.com price target raised to $3,800 from $3,300 at RBC Capital
07/31/20 Guggenheim
Amazon.com price target raised to $3,600 from $2,700 at Guggenheim
07/31/20 Goldman Sachs
Amazon.com price target raised to $4,200 from $3,800 at Goldman Sachs
AAPL Apple
$425.02 /

+39.88 (+10.35%)

07/31/20 Canaccord
Canaccord boosts Apple target to $460 after 'impressive' quarter
07/31/20 RBC Capital
Apple price target raised to $445 from $390 at RBC Capital
07/31/20
Apple price target raised to $460 from $425 at JPMorgan
07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

  • 19
    May
  • 12
    Feb
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

Friday
Recommendations
Barclays backs Overweight on AstraZeneca after Q2 results » 14:44
07/31/20
07/31
14:44
07/31/20
14:44
AZN

AstraZeneca

$55.55 /

-2.35 (-4.06%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis reiterated an Overweight rating and GBp 9,300 price target on AstraZeneca after the company reported "solid and fairly plan" Q2 results. The analyst said the report reaffirmed his view that the story remains one of the most appealing in EU pharma given sustained momentum from the core oncology portfolio supplemented by a fairly consistent string of more positive pipeline newsflow and recent business development.

ShowHide Related Items >><<
AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

AZN AstraZeneca
$55.55 /

-2.35 (-4.06%)

Earnings
Pfizer, BioNTech to supply Japan with 120M doses of BNT162 vaccine candidate » 05:53
07/31/20
07/31
05:53
07/31/20
05:53
PFE

Pfizer

$38.75 /

+0.24 (+0.62%)

, BNTX

BioNTech

$84.02 /

+1.6 (+1.94%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech SE (BNTX) said in a release, "Pfizer and BioNTech announced an agreement with the Ministry of Health, Labour and Welfare, or MHLW, in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and regulatory approval, beginning in 2021. Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses. As requested by the Government of Japan, deliveries of the vaccine candidate are planned for the first half of 2021."

ShowHide Related Items >><<
PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

PFE Pfizer
$38.75 /

+0.24 (+0.62%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

  • 23
    Jul
  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.